|
Patent landscape, scope, and claims: |
United States Patent 5,945,416: Scope, Claims, and U.S. Patent Landscape for Olanzapine-Adjunct Pain Combinations
What does U.S. Patent 5,945,416 claim, at the broadest level?
U.S. Patent 5,945,416 claims compositions and methods for treating pain using:
- Olanzapine (or pharmaceutically acceptable salts/solvates), and
- one or more “Drug Useful in the Treatment of Pain” at specified weight ratios.
The patent’s core claim architecture is “olanzapine + analgesic class agent(s)” with ratio ranges and optional narrowing to:
- NSAIDs (and a defined NSAID subset),
- opioids (and a defined opioid subset),
- alpha-adrenergic agents (explicitly clonidine),
- specific olanzapine polymorph (Form II with a provided XRPD peak list),
- and pain modality (neuropathic, nociceptive, acute),
plus an asserted synergistic analgesic effect.
Claim set at a glance
| Claim group |
Claim numbers |
What is defined |
What is optional or narrowed |
| Composition (genus) |
1 |
Olanzapine + 1+ pain drug(s); ratio from ~1:1 to ~1:1000 |
Later claims narrow pain drug class and ratio |
| Composition (NSAID) |
2-3 |
NSAID pain drugs; defined NSAID list |
Limits to that subset |
| Composition (polymorph) |
4, 24 |
Olanzapine Form II with specified XRPD peaks |
Requires Form II |
| Composition (ratio narrowing) |
6-8, 25-27 |
Ratios down to ~1:30 and ~1:10 |
Requires specific ratio windows |
| Composition (opioids) |
10-14 |
Opioid pain drugs; defined opioid lists |
Subset narrowing in dependent claims |
| Composition (other analgesic classes) |
15-17 |
Includes Tylenol #3, TCAs, anticonvulsants, SSRIs/SNRIs, etc. |
Dependent narrowing to TCA |
| Composition (alpha adrenergic) |
18-21 |
Alpha-adrenergic; clonidine stated |
Dependent narrowing to alpha-adrenergic |
| Composition (synergy) |
22 |
Adds “synergistic analgesic effect” |
Adds a performance assertion |
| Composition (explicit ibuprofen embodiment) |
23-27 |
Olanzapine + ibuprofen; ratio windows |
Requires ibuprofen and optional Form II |
| Method (genus) |
28 |
Administer analgesic dose of olanzapine + pain drug(s) at ratios |
Later claims narrow pain drug class/pain type |
| Method (NSAID, ratio narrowing, polymorph) |
29-32 |
NSAID, ratio windows, Form II requirement |
Dependent narrowing |
| Method (class selections) |
33-34 |
Alpha-adrenergic and opioid; also lists psycho/neuro analgesics |
Dependent selection of class |
| Method (pain types) |
35-37, 42-44 |
Neuropathic/nociceptive/acute |
Dependent selection |
| Method (explicit ibuprofen embodiment) |
38-41 |
Olanzapine + ibuprofen; ratio windows |
Optional Form II + pain type limits |
What is the effective claim scope: composition vs method?
Composition scope
The composition claims are broad in two dimensions:
- Ingredient breadth: olanzapine paired with “one or more Drug Useful in the Treatment of Pain,” with dependent claims enumerating multiple analgesic classes and named drugs.
- Ratio breadth: from about 1 part olanzapine to about 1 to about 1000 parts (upper bound 1000).
Key composition anchors:
- Claim 1 (genus):
“A composition for treating pain comprising olanzapine … and one or more Drug Useful in the Treatment of Pain in a weight ratio of from about one part olanzapine to from about one (1) part to about one thousand (1000) parts Drug Useful in the Treatment of Pain.”
- Claims 6-8 tighten ratio bands to:
- 1:1 to 1:100 (claim 6)
- 1:1 to 1:30 (claim 7)
- 1:1 to 1:10 (claim 8)
- Claim 23 creates an explicit product-type embodiment: olanzapine + ibuprofen within the same ratio envelope; dependent claims narrow to 1:100, 1:30, 1:10.
- Claim 4 locks olanzapine to Form II with a full XRPD peak list.
Method scope
The method claims track the composition claims, shifting from “composition” to “administering an analgesic dose.”
- Claim 28 (genus method): administer an analgesic dose of a composition comprising olanzapine + pain drug(s) at the same ratio range.
- Claims 29-32 add: NSAID selection, specific ratio bands, and Form II requirement.
- Claims 35-37 and 42-44 define pain types:
- neuropathic
- nociceptive
- acute
Practical effect: even if a formulation is not tied to a specific drug class, the method claims can still capture use if the administered formulation matches the ratio + ingredient constraints. If the drug class is one of the enumerated classes (NSAIDs/opioids/alpha-adrenergics/other listed analgesics), those dependent claims further narrow but strengthen enforceability.
How broad are the “Drug Useful in the Treatment of Pain” definitions?
The claims use a functional phrase in claim 1, then dependent claims constrain that phrase via enumerations.
NSAIDs (claims 2-3, and claim 29 via method)
Claim 2: NSAIDs.
Claim 3: NSAID subset includes:
- aspirin
- indomethacin
- ibuprofen
- naproxen
- fenoprofen
- tolmetin
- sulindac
- meclofenamate
- keoprofen
- piroxicam
- flurbiprofen
- diclofenac
(or pharmaceutically acceptable salts)
Claim 5 further narrows: aspirin, ibuprofen, naproxen.
Opioids (claims 10, 11, 12, 13-14 and method claim 33)
Claim 10: opioid compound (composition).
Claim 13: opioid subset includes:
- morphine
- codeine
- meperidine
- methadone
- propoxyphene
- levorphanol
- hydromorphone
- oxymorphone
- oxycodone
- brompton’s cocktail
- pentazocine
- butorphanol
- nabuphine
- buprenorphine
Claim 14 narrows to:
- morphine
- oxymorphone
- oxycodone
- hydromorphone
- codeine
- methadone
Alpha-adrenergics (claims 18-21 and method claim 33)
Claim 18: alpha adrenergic compound.
Claim 19: clonidine (or salt).
Claims 20-21 repeat the alpha-adrenergic limitation for other dependent structures.
“Other analgesic classes” (claims 15-17 and method claim 34)
Claim 15 enumerates multiple classes including:
- Tylenol #3
- tricyclic antidepressants (e.g., desipramine, imipramine, amitriptyline, nortriptyline)
- anticonvulsants (e.g., carbamazepine, gabapentine, valproate)
- serotonin reuptake inhibitors (e.g., fluoxetine, paroxetine, citalopram, sertraline)
- mixed serotonin-norepinephrine reuptake inhibitors (e.g., venlafaxine, duloxetine)
- serotonin receptor agonists and antagonists
- cholinergic (muscarinic and nicotinic) analgesics
- neurokinin antagonists
Claim 17 narrows “Drug Useful in the Treatment of Pain” to a tricyclic antidepressant.
Another composition subset (claim 9)
Claim 9 identifies: morphine, acetaminophen, ibuprofen, diclofenac.
What is special about olanzapine Form II and how does it affect infringement risk?
The patent adds a separate narrowing requirement through Form II olanzapine polymorph with a typical XRPD pattern. This appears in:
- composition claim 4
- composition claim 24
- method claim 32
- method claim 39
Form II XRPD peak list (as recited)
The claims provide interplanar spacing d (Å) values in sequence:
- 10.2689, 8.577, 7.4721, 7.125, 6.1459, 6.071, 5.4849, 5.2181, 5.1251, 4.9874, 4.7665, 4.7158, 4.4787, 4.3307, 4.2294, 4.141, 3.9873, 3.7206, 3.5645, 3.5366, 3.3828, 3.2516, 3.134, 3.0848, 3.0638, 3.0111, 2.8739, 2.8102, 2.7217, 2.6432, 2.6007.
Scope consequence:
If a product uses olanzapine that is not Form II, claims requiring Form II may be avoided. Claims not requiring Form II (e.g., claim 1, 2-3, 6-8, 10-15, etc.) remain available.
Where is the practical “sweet spot” for the patent: ratio and drug class?
The patent repeatedly uses the same ratio architecture:
- Broad: ~1:1 to ~1:1000
- Narrower buckets:
- 1:1 to 1:100 (claims 6, 25, 30, 40)
- 1:1 to 1:30 (claims 7, 26, 31, 41)
- 1:1 to 1:10 (claims 8, 27, 41)
Explicit ibuprofen embodiment
- Claim 23: olanzapine + ibuprofen, ratio 1:1 to 1:1000
- Claim 25: ratio 1:1 to 1:100
- Claim 26: ratio 1:1 to 1:30
- Claim 27: ratio 1:1 to 1:10
- Claim 24: olanzapine Form II in claim 23 context
- Method claims 38-41 mirror the same structure and add pain type options (neuropathic/nociceptive/acute)
Enforcement angle: the ibuprofen-specific dependent claim set can reduce design-around arguments because ibuprofen is listed by name and the ratio ranges are explicit.
How does the patent treat “synergistic analgesic effect”?
- Claim 22 adds: “composition can provide a synergistic analgesic effect.”
This claim is not tied to a specific analgesic class or ratio beyond what claim 1 already provides (it is dependent on claim 1). The phrasing creates an additional characterization layer but does not change ingredient or ratio boundaries.
Method claims by pain modality
The method portion includes dependent claims that specify pain type:
- Neuropathic: claims 35 (composition method claim 28 context), 42 (ibuprofen context)
- Nociceptive: claims 36, 43
- Acute: claims 37, 44
Scope consequence:
If a regimen is marketed, labeled, or used for a particular pain modality, these dependent claims increase coverage specificity. Even if the formulation matches claims 1/28, these modality claims potentially align with clinical and labeling evidence.
U.S. Patent landscape for the olanzapine-analgesic combination space
What this patent covers in the landscape (practical mapping)
Within the U.S., the likely landscape structure around this patent is:
- Drug substance patents for olanzapine (polymorphs and forms) and their processing routes.
- Combination or use patents for olanzapine paired with analgesics (especially NSAIDs/opioids/alpha-adrenergics and centrally acting agents).
- Method-of-treatment patents for olanzapine-adjunct pain indications by pain type (neuropathic/nociceptive/acute).
- Formulation and dosage form patents (not asserted in the provided claims, but common in filed portfolios), such as tablets/capsules, controlled release, and co-administration architectures.
Claim strategy signals in 5,945,416
The claims are structured to capture:
- Product-level combinations (composition claims)
- Use-level combinations (method claims)
- Multiple analgesic pharmacologies: NSAIDs, opioids, alpha-2 agonists (clonidine), and central agents (TCAs, anticonvulsants, SSRIs/SNRIs, neurokinin antagonists, etc.)
- Two abstraction layers: broad functional “Drug Useful in the Treatment of Pain” and then discrete enumerations.
- At least one formulation-critical quality gate: olanzapine Form II with XRPD peaks.
Design-around pressure points
Given the claim wording, the main risk factors for a competitor are:
- Using any enumerated analgesic from dependent claim lists, especially ibuprofen (claims 23-27, 38-41).
- Falling inside ratio bands, especially 1:1 to 1:10 and 1:1 to 1:30, which are repeatedly claimed.
- Using olanzapine Form II if attempting to navigate the polymorph limitation in dependent claims (claims 4, 24, 32, 39).
- Indicating or applying the regimen to neuropathic/nociceptive/acute pain, which aligns with dependent method claims.
Core claim text mapped into enforceable combinations
| Combination pattern |
Claim numbers where it is explicit |
Ingredients |
Ratio envelope |
| Olanzapine + “pain drug” (genus) |
1, 28 |
olanzapine + 1+ drug useful in pain |
~1:1 to ~1:1000 |
| Olanzapine + NSAID (class + subset) |
2-3, 29 |
NSAIDs; aspirin/indomethacin/ibuprofen/naproxen/etc. |
~1:1 to ~1:1000 (unless narrowed) |
| Olanzapine + NSAID (tight subset) |
5 |
aspirin, ibuprofen, naproxen |
depends on upstream ratio |
| Olanzapine + opioid (class + subset) |
10, 13-14, 11-12 and 33 |
opioids listed by name |
depends on upstream ratio |
| Olanzapine + alpha-adrenergic |
18-21, 33 |
alpha-adrenergic; clonidine in claim 19 |
depends on upstream ratio |
| Olanzapine + central analgesic classes |
15-17, 16, 34 |
Tylenol #3; TCAs; anticonvulsants; SSRIs/SNRIs; etc. |
depends on upstream ratio |
| Olanzapine Form II + pain drug |
4, 24, 32, 39 |
Form II olanzapine with XRPD list |
depends on upstream ratio |
| Olanzapine + ibuprofen (explicit) |
23-27, 38-41 |
ibuprofen (explicit) |
1:1 to 1:1000, plus tighter windows to 1:10 |
| Pain-type methods |
35-37, 42-44 |
same formulations; pain modality specified |
same as method claim structure |
Key Takeaways
- U.S. Patent 5,945,416 is a combination-use patent built around olanzapine + an enumerated or functionally defined analgesic at weight ratios from about 1:1 to about 1:1000.
- The enforceable scope spans both composition and method claims, with dependent claim sets that lock in drug class (NSAIDs, opioids, alpha-adrenergics, central analgesic classes), specific named drugs (notably ibuprofen), and pain modality (neuropathic/nociceptive/acute).
- Olanzapine Form II is a specific narrowing element supported by an explicit XRPD peak list, appearing in dependent composition and method claims; products not using Form II may avoid those dependent claims but still face exposure under broader dependent claims not requiring Form II.
- The ratio bands 1:1 to 1:100, 1:1 to 1:30, and 1:1 to 1:10 are repeatedly claimed, which tightens the design-around envelope for combination dosing.
FAQs
1) Does the patent require olanzapine Form II to be infringed?
No. Form II appears in dependent claims (notably claims 4, 24, 32, 39). The broader claims (e.g., claim 1 for composition and claim 28 for method) require olanzapine generally (salt/solvate allowed).
2) What analgesics are explicitly named as NSAIDs under the dependent claims?
A defined list includes aspirin, indomethacin, ibuprofen, naproxen, fenoprofen, tolmetin, sulindac, meclofenamate, keoprofen, piroxicam, flurbiprofen, and diclofenac (claim 3). A tighter subset appears in claim 5: aspirin, ibuprofen, naproxen.
3) Which opioid drugs are enumerated in the patent?
Dependent claims include morphine, codeine, meperidine, methadone, propoxyphene, levorphanol, hydromorphone, oxymorphone, oxycodone, brompton’s cocktail, pentazocine, butorphanol, nabuphine, and buprenorphine (claim 13) and a narrower subset (claim 14).
4) How do the patent’s ratio limits affect combination dosing?
The base ratio is about 1 part olanzapine to about 1 to about 1000 parts of the pain drug(s) (claims 1 and 28). Dependent claims tighten to 1:100, 1:30, and 1:10 (e.g., claims 6-8 and 25-27, plus method counterparts 30-31 and 40-41).
5) Are neuropathic, nociceptive, and acute pain specified in the method claims?
Yes. Neuropathic pain is claimed in claims 35-37 and 42-44 (neuropathic appears in 35 and 42), nociceptive pain appears in 36 and 43, and acute pain appears in 37 and 44.
References
[1] United States Patent 5,945,416 (claim set as provided).
More… ↓
⤷ Start Trial
|
